• CME Group has recently announced plans to launch Nasdaq CME Crypto Index futures in June, pending regulatory review, and to introduce both micro and larger-sized contracts that offer exposure to top cryptocurrencies via a single, financially settled, market-cap weighted futures product.
• By pairing its first market-cap weighted crypto index futures with a planned futures market for GPU-based compute costs, CME Group is moving into emerging areas where derivatives can help standardize pricing for previously opaque digital and AI-related assets.
• We’ll now examine how the planned compute futures tied to GPU benchmarks could reshape CME Group’s investment narrative and growth drivers.

Find 49 companies with promising cash flow potential yet trading below their fair value.

CME Group Investment Narrative Recap

To own CME Group, you generally need to believe that global demand for listed derivatives and risk management tools will remain resilient, even as products evolve. The new Nasdaq CME Crypto Index futures and planned compute futures expand CME’s toolkit, but the most important short term driver still looks like overall trading volumes across core asset classes, while a key risk remains regulatory shifts that could limit participation or constrain new product development. For now, these launches do not appear to materially change that near term balance.

The upcoming compute futures tied to Silicon Data’s GPU benchmarks stand out as particularly relevant here, since they extend CME’s role in pricing and hedging into AI-related infrastructure costs. If these contracts gain traction, they could support the broader catalyst of product diversification across asset classes, potentially offsetting periods when interest rate or equity futures activity is softer and making CME less dependent on any single source of trading volume.

Yet behind the excitement around crypto and compute futures, investors should also be aware of the growing competitive pressure from alternative trading venues and evolving DeFi market structures that could...

CME Group's narrative projects $7.8 billion revenue and $4.6 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a $0.4 billion earnings increase from $4.2 billion today.

Uncover how CME Group's forecasts yield a $306.60 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community currently estimate CME’s fair value between US$248.05 and US$306.60, reflecting a wide spread in expectations. Against that backdrop, CME’s push into crypto and GPU compute futures highlights how new products could influence future volumes and fee mix, so it is worth comparing several of these viewpoints before forming your own opinion.

Explore 4 other fair value estimates on CME Group - why the stock might be worth 15% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your CME Group research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free CME Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CME Group's overall financial health at a glance.

Looking For Alternative Opportunities?

Our top stock finds are flying under the radar-for now. Get in early:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 27 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.